Roche Hldg Ltd Spons: (OTC: RHHBY)
$65.56
-0.09 (-0.14%)
Volume 1,785,365
May 23 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 64.33 - 65.90 |
| 52wk Low - High | 38.61 - 66.52 |
| Previous Close | 65.65 |
| Avg. Volume | 358,940 |
| Industry | LARGE CAP PHARMA |
| Market Cap | 226.51 B |
| Div - Yield | 1.62 - 2.47 |
| Beta | 0.67 |
| PE (Forward) | 16.52 |
| Current Year Est. | 3.97 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
No Zacks Recommendation |
Zacks Industry Rank
|
171 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 16.52 |
| PEG Ratio | 2.15 |
| Current Year Est. | 3.97 |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 04-30-2013 |
| EPS Last Year | NA |
| Expected Earnings Growth | 7.69% |
Company Description
Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (03/2013) |
Next Qtr (06/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | 3.97 | 4.27 |
| Number of Estimates | 0 | 0 | 3 | 3 |
| Low Estimate | NA | NA | 3.91 | 4.18 |
| High Estimate | NA | NA | 4.04 | NA |
| Year Ago EPS | NA | NA | 3.69 | 3.97 |
| EPS Growth | NA | NA | 7.68% | 7.47% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ROCHE HLDG LTD | RHHBY | 65.65 | |
|
| ABBOTT LABS | ABT | 37.72 | |
|
| ABBVIE INC | ABBV | 46.76 | |
|
| ALLERGAN INC | AGN | 97.73 | |
|
| ASTRAZENECA PLC | AZN | 52.35 | |
|
| BAYER A G -ADR | BAYRY | 109.20 | |
|
| BRISTOL-MYERS | BMY | 46.40 | |
|
| GLAXOSMITHKLINE | GSK | 52.94 | |
|
| JOHNSON & JOHNS | JNJ | 88.46 | |
|
| LILLY ELI & CO | LLY | 54.92 | |
|
Sector:Medical>> Industry:LARGE CAP PHARMA
COMPARE TICKER vs. Its Peers
Zacks Commentary
Positive Data on Roche Candidate
May 22, 2013
Positive Data on Novartis' Afinitor
May 21, 2013
Good News for Roche's Tarceva
May 16, 2013
Pipeline Progress at Gilead
May 16, 2013
Nektar Posts Wider Loss, Maintains View
May 15, 2013
Lilly Scraps Oncology Candidate
May 13, 2013
PDL BioPharma Misses Earnings Ests
May 13, 2013
Narrower-than-Expected Loss at Seattle Genetics
May 08, 2013
Financials
| EPS TTM | NA |
| Sales | 49,208 |
| Net Income | NA |
| Price/Earnings | NA |
| Price/Book | 12.69 |
| Price/Cash Flow | 14.93 |
| Price/Sales | NA |
News
Roche Holding's Shares Changing Hands at Higher Prices on 2.9x Above-Average Volume (RHHBY) - Financial News Network Online - Unusual Volume
May 23, 2013
Wall Street Loves this New Immunotherapy Cancer Drug - TheMotleyFool
May 22, 2013
1 Big Pharma Phase 3 Failure - TheMotleyFool
May 21, 2013
Will ASCO Unlock Big Value in This Cancer Drug Class? - TheMotleyFool
May 18, 2013
Cancer cocktail shows promise - Investors Business Daily
May 17, 2013
ASCO `13 Preview: New `Anti-PD-1` Therapies Shrink Tumors - TheStreet.com
May 15, 2013
ASCO `13 Preview: Roche`s Next-Gen Rituxan Steps Up - TheStreet.com
May 15, 2013
Cancer Meeting Highlights the Good and Bad of the Immune System - TheMotleyFool
May 15, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 4 |
| Average Target Price | 58.90 |
| Industry Rank by ABR | 171 out of 265 |
| Rank in Industry | 1 out of 15 |
